10.06.2013 - British Alliance Pharma plc has bought the complete rights for Novartis’ obstetric drug Syntometrine.
The Chippenham-based specialty company already owns the UK rights to Syntometrine, an obstetric drug used in the final stage of labour. With the US$11.5m deal, Alliance Pharma adds Novartis’ assets in other countries to its portfolio.
The Novartis Group has been selling Syntometrine in Australia, South Africa, Malaysia and New Zealand. In the year from March 2012 to March 2013, the Swiss drug giant made US$3.2m in sales with Syntometrine; the gross margin generated was US$2.8m. Alliance Pharma estimates its annual distribution and operating costs associated with the new territories at US$780,000.
The British company, which generates annual sales of US$69.8m last year, will finance the deal from existing cash and bank facilities, including a US$5.4m drawdown from the group's US$40.7m acquisition facilities. This leaves US$15m of the facilities available to fund further acquisitions.
23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.
21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.